”After years of research we suddenly realised how to combine our findings. It was a eureka moment.”

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

How antimicrobial hydrogel can revolutionize clinical treatments

Binds and kills 99.99% of bacteria without harming the body – even resistant bacteria

Introducing Amferia wound dressing for animal care — binds and kills bacteria without harming the body

Antimicrobial dressing:

Amferia has invented a new antimicrobial hydrogel that  targets, binds, and rapidly kills upto 99.99% of bacteria upon contact. The hydrogel consists of amphiphilic antibacterial polymers mimicking the immune system. This makes it completely safe for the body and the hydrogel does not release anything into the wound.

Amferia is producing a veterinary antimicrobial hydrogel wound dressing, expected to be introduced in late 2022, available for pre-orders now.

Appropriate for acute and low exuding wounds, like post-surgical incisions, this product can be used as a free-standing hydrogel pad supported on the wound by a secondary dressing, or as a fully adhesive dressing.

Meant exclusively for veterinary in-clinic use, like surgical care units or in-patient care, all products are supplied sterile and will include instructions for use.  

Read more about the science behind Amferia's products >

Amferia non-adhesive hydrogel dressing

Product description:

Our free-standing hydrogel dressing is currently available for purchase in three standard sizes. The pad is non-adhesive sheet of hydrogel that can be applied directly to a wound bed.

The dressing is non-adhesive to wound and requires secondary surgical-grade dressing to hold it in place, which Amferia will provide with shipment. Alternatively, customers can use a secondary dressing of their choice. We may also be able to provide custom sizes of the hydrogel pad upon request.

Please contact us with your request >

Easily adaptable to wound, custom sizes can be ordered, can be used with transparent film or absorbent dressings.

  • Hydrogel sizes and product article numbers
  • 1. 4 x 7.5 cm —10085475
  • 2. 4 x 15 cm — 10085415
  • 3. 5 x 20 cm — 10085520
  • We may also be able to provide custom sizes of the hydrogel dressing upon request.

Product Video — How to use the Amferia non-adhesive hydrogel dressing

Amferia adhesive hydrogel dressing

Coming product:

The adhesive hydrogel dressing will be available for purchase from 2023. At present, we offer the adhesive dressings on a trial basis for case feedback on dry to low exuding wounds. We are interested to collaborate with clinics interested to try the products or discus clinical investigations.

Please contact us to discuss further or request a product specification document >

Evidence of safety and efficacy in post-surgical wounds

Case studies:

Amferia has collaborated with five leading veterinary clinics across Europe and performed over 100 case studies on a variety of post-surgical wounds of cats and dogs.

Amferia’s hydrogel dressing enabled safe healing of the wound with no complications. Furthermore, the product could be adapted easily to the complex contours of the animal’s body and adjusted to the required size.

The surgeons who used the dressings have provided excellent feedback on the usability, safety and the existing evidence on antimicrobial efficacy.

Infected wounds — killing multi-resistant bacteria

Chronic wounds:

Case studies involving Amferia hydrogel dressings have been performed on infected chronic wounds in collaboration with two clinics in Germany and the Netherlands.

Together with Amferia, the clinics have performed six case evaluations of the Amferia hydrogel dressing in hard-to-heal infected wounds of one dog and five cats, all colonized with multi-resistant pseudomonas aeuruginosa or MRSA bacteria. 

All wounds were open wounds from either trauma or chronic complications, and the patients suffered from recurring wound complications over a period of two to three months. The attending wound specialist requested Amferia dressing for trials on the patients and noted a clear effect within 24 hours, noting bio-burden reduction and formulation of new granulation tissue.

100 times reduction of bacterial load in deep infected wounds

In-vivo study:

Amferia collaborated on an in-vivo infection model study with Chalmers University and the Department of Biomaterials at Sahlgrenska University. 

The study results published in ACS Biomaterials Science, was a wound model in mice heavily infected with bacteria. The results demonstrated 100 times reduction of bacterial load in the wounds treated with the amphiphilic antimicrobial hydrogel.  

This is especially impressive, given that the wound was deep and the bacterial load was extremely high. The results demonstrated the strong effect the hydrogels had on bacterial removal, solely upon contact and without releasing any substances, from the wound in a statistically significant manner. 


What clinicians say:

  • "It was very easy and fits very well"
  • Dr Christian Ness, Anicura Weingarten
  • "We are very pleased with your product. Can we get an offer?”
  • Dr Ulrich Schmidt, Veterinary clinic Wandsbek
  • "Granulation tissue observed and visible change in bioburden"
  • Dr Peter Engelhardt, Anicura Haan, Germany

How to buy Amferia’s hydrogel wound dressing

Order now:

Amferia Antimicrobial Hydrogel Dressing is available for purchase in Sweden through our distributor, Triolab AB.

The currently available product for purchase is the free-standing hydrogel dressing, provided in 3 standard sizes. A sheet of hydrogel that can be applied directly to the wound bed and is non-adhesive to wound.

Please contact our Sales Director Saba Atefyekta (PhD) for ordering information >

Collaborate with us and receive samples for trials. Amferia is happy to provide samples of our current and upcoming products for early trials for post-surgical and other dry-to-low exuding wound applications.

Please contact our Product Manager Rojan Modaresi (DVM, PhD) with your interest for product trials >

Agneta Edberg appointed chairperson

July 28, 2022

Agneta has a solid background from the global Life science and Medtech field spanning over 30 years in leading roles such as; Sales &Marketing Director of Pharmacia (Pfizer), Senior VP and CEO of Mylan NordicPharmaceuticals, CEO of NM Pharma and more recently as the COO of Bactigaurd that manufactures a variety of antimicrobial device. Today, she works on theBoard of cutting-edge life-science SME’s guiding the companies for future success. Agneta’s extensive knowledge in the life science industry will be important for Amferia’s scale-up journey in both human and animal wound care.

Anand Kumar Rajasekharan, CEO of Amferia − “It is an honour to work with Agenta, whose impressive knowledge of the field and guidance greatly strengthens Amferia’s position as a competent and cutting-edge SME. We look forward to jointly achieve the upcoming key milestones such as the first product launch for animal health, FDA and CE regulatory processes for human health and establishing a successful sales and marketing foundation for Amferia.”

Agneta Edberg − “Amferia is a company every board person wishes to work for. The technology offers a paradigm shift in wound care with nontoxic properties still killing bacteria, even the resistant ones. In a world where antimicrobial resistance is an increasing challenge to humanity, I am grateful to be a part of reducing that threat”

Amferia at the European Wound Management Association (EWMA) congress 2022 in Paris

May 17, 2022

EWMA is an important congress that brings together clinicians and healthcare  industry for important discussions within wound care for humans and animals. Amferia is eager to present our science, antimicrobial technology and introduce our first wound dressings for animal and human wound  care. We welcome all attendees to our stand located in

room 252A at the  congress venue, Palais  des Congrès de Paris, to know more about Amferia and  clinical evidence for human and animal wound care as well as for an  introduction to our soon-to-be launched wound dressings for animal wound  care. We also invite all  attendees to our scientific talk at the symposium for Veterinary Wound  Healing Association (VWHA) on 24th May at 08:45 hrs room 252A.

Amferia granted US patent for its antimicrobial material platform

May 9, 2022

Amferia AB announced today that it has been granted the foundational patent by the United States Patent and Trademark Office (USPTO)for its innovative antimicrobial material based on an amphiphilic antimicrobial hydrogel. The company is now in its final stages of product development for wound care applications and aims to launch the first product within animal health during 2022.

Top 100 research based innovations of 2021

May 26, 2021

Amferia’s technology recognized as one of the top 100 research based innovations of 2021 by the Royal Swedish Academy of Engineering Sciences.

Amferia & Triolab announce partnership to launch innovative wound care products for animal health

May 6, 2021

The joint partnership with Triolab will enable Amferia to reach the large Swedish veterinary market where wound care and infection prevention is of prime importance, which has been intensified with the growing threat of antibiotic resistant infections. Amferia and Triolab’s partnership will build on extensive data and feedback from Amferia’s ongoing product trials across Europe. The joint efforts will aim to market the products to selective veterinary clinics across Sweden during 2021 and further expansion in 2022.

Amferia raises SEK 6.2 million in pre-seed investment

January 22, 2020

Almi Invest, Chalmers Ventures, along with the British investor Corithinan Properties Ltd. and Let’s Deal Founder Alexander Hars have invested a total of SEK 6.2 million in the Gothenburg-based med-tech company Amferia, who has developed a wound care product with a patented material that actively combats infections and kills antibiotic-resistant bacteria.

“Every year, 700,000 people die globally as a result of infections caused by antibiotic-resistant bacteria and almost half of the infections begin with a simple wound on the skin. Amferia's wound care solution is a game-changer and will save lives”, says Louise Warme, Investment Manager at Almi Invest.

Amferia establishes R&D operations at AstraZeneca’s BioVentureHub

October 28, 2019

Amferia is very excited to move into the BioVentureHub, given the strong benefits of operating in a flourishing environment with state-of-the-art infrastructure dedicated to medtech and life science companies. We are also eager to be around so many experts within life science ranging from established to early-stage companies researching in biopharmaceuticals, medical devices and diagnostics. Amferia looks forward to be part of, learn and grow in this supportive and exciting community.

At the Annual Veterinary Hygiene Conference 2019

October 24, 2019

We had the pleasure to attend the annual Veterinary Hygiene Conference in Knivsta, Stockholm. One of the primary questions of this conference was about handling antibiotic resistant infections in animal wound care – a fast growing problem in Sweden and Globally. Many interesting & enlightening discussions with expert veterinary clinicians taught us a lot about the needs and challenges in animal wound care and how Amferia might expand its innovative solutions to help veterinary healthcare. Thanks for a great conference VVHF.

Amferia wins the Start-up of the Year award at Venture Cup Sweden 2019

September 20, 2019

The Jury's motivation for choosing Amferia as the winners! “With its disruptive solution, the team has the opportunity to shake several industries as they tackle one of humanity’s greatest global threats. By addressing a world problem, millions of lives will be saved. By changing the behavior of the consumer, there is also the potential to reform the market.”

Amferia receives the prestigious EU SME Instrument (Phase 1) grant from the European Union

August 1, 2019

Amferia receives the highly competitive and coveted EU SME Instrument Phase 1 grant of 50 000 Euros along with the valuable business network to take forward our technology into the market.